(E)-4-(2-(6-iodobenzofuran-2-yl)vinyl)-N,N-dimethylaniline | 1089681-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (E)-4-(2-(6-iodobenzofuran-2-yl)vinyl)-N,N-dimethylaniline
• 英文别名: 4-[(1E)-2-(6-iodo-1-benzofuran-2-yl)ethenyl]-N,N-dimethylbenzenamine；6-iodo-2-(4-dimethylaminostyryl)benzofuran；4-(2-(6-iodobenzofuran-2-yl)vinyl)-N,N-dimethylbenzenamine；4-[(E)-2-(6-iodo-1-benzofuran-2-yl)ethenyl]-N,N-dimethylaniline
• CAS: 1089681-55-9
• 化学式: C₁₈H₁₆INO
• 分子量: 389.236
• InChiKey: MUVUVGAWOQPUGI-BJMVGYQFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  16.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  diethyl ((6-bromobenzofuran-2-yl)methyl)phosphonate 在 四(三苯基膦)钯 、 碘 、 sodium methylate 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 氯仿 为溶剂， 反应 19.0h， 生成 (E)-4-(2-(6-iodobenzofuran-2-yl)vinyl)-N,N-dimethylaniline
  参考文献：
  名称：

  放射性ヨウ素標識化合物、及び、これを含む放射性医薬

  摘要：

  提供同时具有τ亲和性和淀粉样蛋白亲和性的放射性碘标记化合物。本发明涉及含有N，N-二甲基苯胺基团的放射性碘标记化合物或其盐。【选择图】无

  公开号：

  JP2015089879A

文献信息

• STYRYLBENZOFURAN DERIVATIVES AS INHIBITORS FOR BETA-AMYLOID FIBRIL FORMATION AND PREPARATION METHOD THEREOF
  申请人：Kim Dong Jin

  公开号：US20110124888A1

  公开（公告）日：2011-05-26

  The present invention relates to a novel compound which efficiently inhibits the formation of beta-amyloid fibrils in the brain to be useful for preventing or treating a degenerative brain disease, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient.

  本发明涉及一种新型化合物，能够有效抑制大脑中β-淀粉样蛋白纤维的形成，可用于预防或治疗退行性脑疾病，以及制备该化合物的方法和包含其作为活性成分的药物组合物。
• 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
  申请人：国立大学法人京都大学

  公开号：JP2015089879A

  公开（公告）日：2015-05-11

  【課題】タウ親和性とアミロイド親和性とを併せ持つ、放射性ヨウ素標識化合物を提供する。【解決手段】本発明は、Ｎ，Ｎ-ジメチルベンゼンアミン部位を含む放射性ヨウ素標識化合物又はその塩である。【選択図】なし

  提供同时具有τ亲和性和淀粉样蛋白亲和性的放射性碘标记化合物。本发明涉及含有N，N-二甲基苯胺基团的放射性碘标记化合物或其盐。【选择图】无
• Aminostyrylbenzofuran derivatives as potent inhibitors for Aβ fibril formation
  作者：Ji Hun Byun、HyeYun Kim、YoungSoo Kim、Inhee Mook-Jung、Dong Jin Kim、Won Koo Lee、Kyung Ho Yoo

  DOI：10.1016/j.bmcl.2008.08.111

  日期：2008.10

  The synthesis of a novel series of aminostyrylbenzofuran derivatives 1a-w and their inhibitory activities for A beta fibril formation were described. All the synthesized compounds were evaluated by thioflavin T (ThT) assay and displayed potent inhibitory activities for A beta fibril formation. Among them, compounds 1i and 1q exhibited excellent inhibitory activities (IC(50) = 0.07 and 0.08 mu M, respectively) than those of Curcumin (IC(50) = 0.80 mu M) and IMSB (IC(50) = 8.00 mu M) as reference compounds. Both compounds were selected as promising candidates for further biological evaluation. (C) 2008 Elsevier Ltd. All rights reserved.
• Structure–Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimer’s Disease Brains
  作者：Kenji Matsumura、Masahiro Ono、Ayane Kitada、Hiroyuki Watanabe、Masashi Yoshimura、Shimpei Iikuni、Hiroyuki Kimura、Yoko Okamoto、Masafumi Ihara、Hideo Saji

  DOI：10.1021/acs.jmedchem.5b00440

  日期：2015.9.24

  In order to explore novel tau-imaging agents that can selectively detect neurofibrillary tangles in Alzheimer's disease (AD) brains, we designed and synthesized a series of heterocyclic phenylethenyl and (3-pyridinyl)ethenyl derivatives with or without a dimethyl amino group. In in vitro autoradiography using AD brain sections, all radioiodinated ligands with a dimethyl amino group bound to A beta deposits in the sections. In contrast, the ligands without a dimethyl amino group showed different patterns of radioactivity accumulation in the sections depending on the kind of heterocycle contained in their molecules. Particularly, a phenylethenyl benzimidazole derivative ([I-125]64) showed marked radioactivity accumulation in the temporal lobe which corresponded with the distribution of tau deposits. [I-125]64 also showed the most favorable pharmacokinetics in normal mouse brains (3.69 and 0.06% ID/g at 2 and 60 min postinjection, respectively) among all ligands in this study. Taken together, these results suggest that [I-123]64 may be a new candidate tau-imaging agent.